corp_html/html/AboutUs-Main.htm

<p align=center><img src="p/pliva_president.gif" width="269" height="16"></p>
<p align=left><img src="p/president.jpg" width="105" height="125" align="left" vspace="5" hspace="10" border="1"></p>
<p align=left> 
  <b>Welcome to PLIVA!</b></p>
<p align=left> 
  I would like to take this opportunity to welcome and introduce you to PLIVA,
the leading pharmaceutical company in Central and Eastern Europe.  Since its 1996
listing on the London and Zagreb Stock Exchanges, PLIVA has made notable
advancements in internationalising its business and implementing a global and
innovative strategy. PLIVA represents a rather unique company with investments
in both research and development. With over 400 patents in possession, PLIVA has
proven the high calibre of its R&D capabilities, most notably through its
discovery of the blockbuster azithromycin. This macrolide antibiotic, globally
known as Zithromax (under license by Pfizer) or Sumamed (PLIVA brand), represents
the top selling antibiotic of its class. Building on a long history of R&D
expertise and innovation, PLIVA has developed a strong NCE and Generics
programmes,
an invaluable investment for PLIVA's sustainable growth. Our business model and
processes represent an optimal combination of these R&D activities with
international expansion, through which PLIVA will continue to grow and create
shareholder value. </p>
<p align=left>I am very proud of PLIVA's accomplishments, but most of all, I take
pride in our people who made these advancements possible. The innovation and
commitment of scientists and technicians of PLIVA's Research Institute has led to
the discovery of azithromycin as well as the start of clinical trials for a
number of new drugs and the development of over 40 new generic drugs. 
  </p>
<p align=left> The commitment to quality demonstrated by the PLIVA team,
including top management through production staff line staff, has gained our
customers trust in our products. PLIVA's marketing and sales teams have focused
their attention on customer needs - not only on satisfying their needs, but also
exceeding their expectations. These values and approach are an integral part of
PLIVA's operations worldwide.</p>
 <p align=left>PLIVA 
  is people dedicated to helping other people around the world live healthier 
  and longer lives by providing innovative, high quality medicines and solutions.</p>
<p align=left> 
  Zeljko Covic </p>
</body>
</html>
1	dpavlin	1.2	<p align=center><img src="p/pliva_president.gif" width="269" height="16"></p>
2			<p align=left><img src="p/president.jpg" width="105" height="125" align="left" vspace="5" hspace="10" border="1"></p>
3			<p align=left>
4			<b>Welcome to PLIVA!</b></p>
5			<p align=left>
6			I would like to take this opportunity to welcome and introduce you to PLIVA,
7			the leading pharmaceutical company in Central and Eastern Europe. Since its 1996
8			listing on the London and Zagreb Stock Exchanges, PLIVA has made notable
9			advancements in internationalising its business and implementing a global and
10			innovative strategy. PLIVA represents a rather unique company with investments
11			in both research and development. With over 400 patents in possession, PLIVA has
12			proven the high calibre of its R&D capabilities, most notably through its
13			discovery of the blockbuster azithromycin. This macrolide antibiotic, globally
14			known as Zithromax (under license by Pfizer) or Sumamed (PLIVA brand), represents
15			the top selling antibiotic of its class. Building on a long history of R&D
16			expertise and innovation, PLIVA has developed a strong NCE and Generics
17			programmes,
18			an invaluable investment for PLIVA's sustainable growth. Our business model and
19			processes represent an optimal combination of these R&D activities with
20			international expansion, through which PLIVA will continue to grow and create
21			shareholder value. </p>
22			<p align=left>I am very proud of PLIVA's accomplishments, but most of all, I take
23			pride in our people who made these advancements possible. The innovation and
24			commitment of scientists and technicians of PLIVA's Research Institute has led to
25			the discovery of azithromycin as well as the start of clinical trials for a
26			number of new drugs and the development of over 40 new generic drugs.
27			</p>
28			<p align=left> The commitment to quality demonstrated by the PLIVA team,
29			including top management through production staff line staff, has gained our
30			customers trust in our products. PLIVA's marketing and sales teams have focused
31			their attention on customer needs - not only on satisfying their needs, but also
32			exceeding their expectations. These values and approach are an integral part of
33			PLIVA's operations worldwide.</p>
34			<p align=left>PLIVA
35			is people dedicated to helping other people around the world live healthier
36			and longer lives by providing innovative, high quality medicines and solutions.</p>
37			<p align=left>
38			Zeljko Covic </p>
39			</body>
40			</html>